Your browser doesn't support javascript.
loading
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
Chen, Esther Z; Jacobson, Blake A; Patel, Manish R; Okon, Aniekan M; Li, Shui; Xiong, Kerry; Vaidya, Abhishek J; Bitterman, Peter B; Wagner, Carston R; Kratzke, Robert A.
Affiliation
  • Chen EZ; Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
Invest New Drugs ; 32(4): 598-603, 2014 Aug.
Article in En | MEDLINE | ID: mdl-24711125
ABSTRACT
Deranged cap-mediated translation is implicated in the genesis, maintenance and progression of many human cancers including mesothelioma. In this study, disrupting the eIF4F complex by antagonizing the eIF4E-mRNA-cap interaction is assessed as a therapy for mesothelioma. Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex. Colony formation was measured in mesothelioma treated with 4Ei-1 alone or combined with pemetrexed. Proliferation was examined in cells treated with 4Ei-1. Binding to a synthetic cap-analogue was used to study the strength of eIF4F complex activation in lysates exposed to 4Ei-1. 4Ei-1 treatment resulted in a dose dependent decrease in colony formation and cell viability. Combination therapy of 4Ei-1 with pemetrexed further reduced colony number. Formation of eIF4F cap-complex decreased in response to 4Ei-1 exposure. 4Ei-1 is a novel prodrug that reduces proliferation, represses colony formation, diminishes association of eIF4F with the mRNA cap, and sensitizes mesothelioma cells to pemetrexed.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Protein Biosynthesis / Prodrugs / Oncogene Proteins / Mesothelioma Limits: Humans Language: En Year: 2014 Type: Article

Full text: 1 Database: MEDLINE Main subject: Protein Biosynthesis / Prodrugs / Oncogene Proteins / Mesothelioma Limits: Humans Language: En Year: 2014 Type: Article